5,252 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 5,252 shares of the company’s stock, valued at approximately $660,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Neurocrine Biosciences during the 1st quarter worth about $1,460,000. Financiere des Professionnels Fonds d investissement inc. purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth about $696,000. Wealth Enhancement Advisory Services LLC raised its stake in shares of Neurocrine Biosciences by 229.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 19,107 shares of the company’s stock worth $2,467,000 after purchasing an additional 13,301 shares in the last quarter. Golden State Wealth Management LLC raised its stake in shares of Neurocrine Biosciences by 116.9% during the 1st quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock worth $44,000 after purchasing an additional 214 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its stake in shares of Neurocrine Biosciences by 167.2% during the 1st quarter. Integrated Wealth Concepts LLC now owns 7,233 shares of the company’s stock worth $800,000 after purchasing an additional 4,526 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the sale, the director owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Morgan Stanley raised their price objective on Neurocrine Biosciences from $163.00 to $168.00 and gave the company an “overweight” rating in a research note on Monday, October 20th. Zacks Research raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 15th. Canaccord Genuity Group raised their price objective on Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, The Goldman Sachs Group initiated coverage on Neurocrine Biosciences in a research note on Thursday, July 10th. They issued a “buy” rating and a $182.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $168.00.

Neurocrine Biosciences Stock Down 6.4%

NBIX opened at $138.02 on Thursday. The firm has a market capitalization of $13.69 billion, a P/E ratio of 33.02, a price-to-earnings-growth ratio of 1.01 and a beta of 0.21. The stock’s 50 day moving average price is $140.64 and its two-hundred day moving average price is $129.12. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $154.61.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, October 28th. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.46. The firm had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. Neurocrine Biosciences had a return on equity of 16.42% and a net margin of 15.95%.The company’s revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.81 EPS. As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.